Cencora income statement

In fiscal 2025, Cencora reported revenue of $321.33bn, up 9.3% on the year before, operating income of $2.63bn (a 0.8% margin) and net income of $1.55bn, or $7.96 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ billions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Cencora: income statement, annual
Fiscal year	2009Sept 2009	2010Sept 2010	2011Sept 2011	2012Sept 2012	2013Sept 2013	2014Sept 2014	2015Sept 2015	2016Sept 2016	2017Sept 2017	2018Sept 2018	2019Sept 2019	2020Sept 2020	2021Sept 2021	2022Sept 2022	2023Sept 2023	2024Sept 2024	2025Sept 2025	LTMJun 2026
Revenue	71.8	77.8	78.7	78.1	88.0	119.6	136.0	146.8	153.1	167.9	179.6	189.9	214.0	238.6	262.2	294.0	321.3	332.8
Cost of revenue	—	—	—	—	—	—	—	142.6	148.6	163.3	174.5	184.7	207.0	230.3	253.2	284.0	309.9	319.6
Gross profit	2.1	2.3	2.5	2.6	2.5	3.0	3.5	4.3	4.5	4.6	5.1	5.2	6.9	8.3	9.0	9.9	11.5	13.2
Selling, general and administrative	1.1	1.2	1.1	1.2	1.3	1.6	1.9	2.1	2.1	2.5	2.7	2.8	3.6	4.8	5.3	5.7	6.5	7.7
Operating income	0.9	1.1	1.2	1.3	0.9	0.8	0.4	1.5	1.1	1.4	1.1	−5.1	2.4	2.4	2.3	2.2	2.6	3.0
Net interest income	−0.1	−0.1	−0.1	−0.1	−0.1	−0.1	—	—	—	—	—	—	—	—	—	—	—	—
Income before tax	0.8	1.0	1.1	1.2	0.8	0.7	0.3	1.4	0.9	1.2	1.0	−5.3	2.2	2.2	2.2	2.0	2.3	3.6
Income tax	0.3	0.4	0.4	0.5	0.3	0.4	0.4	−0.0	0.6	−0.4	0.1	−1.9	0.7	0.5	0.4	0.5	0.7	1.0
Net income	0.5	0.6	0.7	0.7	0.4	0.3	−0.1	1.4	0.4	1.7	0.9	−3.4	1.5	1.7	1.7	1.5	1.6	2.6
Diluted EPS	$1.66	$2.22	$2.54	$2.80	$1.84	$1.16	−$0.63	$6.32	$1.64	$7.53	$4.04	−$16.65	$7.39	$8.04	$8.53	$7.53	$7.96	$13.46
Diluted shares (average)	303m	287m	278m	257m	235m	235m	218m	226m	222m	220m	212m	205m	208m	211m	205m	200m	195m	195m
EBITDA	1.0	1.2	1.3	1.4	1.1	1.0	0.7	1.9	1.5	1.9	1.6	−4.7	2.9	3.1	3.3	3.3	3.7	4.1

US$ billions unless shown otherwise. Fiscal quarters.

Cencora: income statement, quarterly
Quarter	2024 Q4Sept 2024	2025 Q1Dec 2024	2025 Q2Mar 2025	2025 Q3Jun 2025	2025 Q4Sept 2025	2026 Q1Dec 2025	2026 Q2Mar 2026	2026 Q3Jun 2026
Revenue	79.1	81.5	75.5	80.7	83.7	85.9	78.4	84.8
Cost of revenue	76.6	78.9	72.4	77.8	80.8	82.9	74.8	81.1
Gross profit	2.5	2.6	3.1	2.9	3.0	3.1	3.6	3.6
Selling, general and administrative	1.5	1.5	1.6	1.7	1.7	1.8	2.0	2.1
Operating income	0.1	0.7	1.0	0.9	0.0	0.8	1.1	1.1
Income before tax	0.1	0.6	0.9	0.9	−0.2	0.7	2.1	1.0
Income tax	0.1	0.1	0.2	0.2	0.1	0.1	0.5	0.2
Net income	0.0	0.5	0.7	0.7	−0.3	0.6	1.6	0.8
Diluted EPS	$0.04	$2.50	$3.68	$3.52	−$1.74	$2.87	$8.40	$3.94
EBITDA	0.9	1.0	1.3	1.1	0.3	1.0	1.4	1.4

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: COR vs MCK COR vs HSIC COR vs YI

More: Health Care Distributors stocks compared, Health Care sector, rankings of US companies

Figures from Cencora's SEC filings (10-K and 10-Q), retrieved October 20, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Cencora.